HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.

AuthorsThilo Zander, Thomas Pabst, Sämi Schär, Stefan Aebi, Ulrich Mey, Urban Novak, Erika Lerch, Gaëlle Rhyner Agocs, Jeroen Goede, Zuzanna Maniecka, Stefanie Hayoz, Axel Rüfer, Christoph Renner, Christoph Driessen
JournalLeukemia (Leukemia) Vol. 37 Issue 3 Pg. 699-701 (03 2023) ISSN: 1476-5551 [Electronic] England
PMID36635391 (Publication Type: Multicenter Study, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • pomalidomide
  • Thalidomide
  • Dexamethasone
Topics
  • Humans
  • Multiple Myeloma (drug therapy)
  • Thalidomide
  • Neoplasms, Plasma Cell
  • Dexamethasone
  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasm Recurrence, Local (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: